Worldwide: Advocate General Of The CJEU Opines That Cmss Are Co-Responsible For Marketing Authorisations Granted Under The DCP

The Opinion of Advocate General Bobek (AG) was handed down last week in case C-557/16, Astellas Pharma GmbH, regarding the role of the Concerned Member States (CMSs) in the Decentralised Procedure (DCP).1 During the DCP, the Reference Member State (RMS) has primary responsibility for preparing the assessment report on the medicinal product, and CMSs can raise questions or objections on the grounds of a potential serious risk to public health. This case, a referral from the Finnish Court, asks whether, and if so how, administrative and legal questions, such as the length of the regulatory data protection period (RDP), should be resolved in the CMSs, considering that national marketing authorisations (MAs) are granted at the end of the DCP.

The AG has opined that CMSs can raise issues as to RDP during the assessment phase and are co-responsible for the documents approved in that procedure. However, once agreement has been reached, CMSs cannot unilaterally revisit that decision. After authorisation, the courts of CMSs are competent to review the determination of the national competent authority.


The case concerns Astellas's product, Ribomustin (bendamustine). The first medicinal product containing bendamustine obtained MA in the former German Democratic Republic (GDR) in 1971 under the tradename Ribomustin. In 1990, Germany was reunified. In accordance with transitional provisions allowing medicinal products that had been on the market in the GDR to remain on the market in Germany, Ribomustin was deemed to have a MA without the submission of any pre-clinical or clinical data. In 2005, following submission of data by Astellas, the German competent authority (BfArM) issued a re-registration of Ribomustin, but only for two of the four indications attached to the original product. However, due to certain deficiencies in the renewal procedure, Astellas always believed that the MA was not granted in accordance with the relevant EU pharmaceutical law. Astellas, therefore, applied for an MA for Levact, another bendamustine product. In 2010, following the authorisation of Levact, Astellas withdrew Ribomustin from the German market.

In 2012, Helm AG submitted an application for a (generic) copy of Levact using the DCP with Denmark as the RMS and Finland and Norway as CMSs. The application cited Levact (the bendamustine product authorised in 2010) as the reference medicinal product. The Danish competent authority considered that Levact belonged to the same global marketing authorisation as Ribomustin (granted by BfArM in 2005), and therefore the RDP had expired and generic MAs could be granted.

Astellas challenged the grant of generic MAs in all three countries saying that the 2005 MA was not granted in accordance with EU law and thus could not start time running for the purposes of RDP. An originator's RDP starts to run from the date of the grant of the first authorisation in the EU granted in accordance with EU provisions in force. Astellas contended that the first such authorisation was granted in 2010 for Levact. Helm disagreed and also argued that Astellas could not properly challenge the status of the 2005 German authorisation in Finland as a CMS could only object to the assessment of the RMS on public health grounds and not on RDP grounds. In Finland, the Higher Administrative Court referred a number of questions to the Court of Justice of the European Union (CJEU) about the role of the national competent authority and the national court in a CMS and their ability to question the assessment of the RMS in relation to RDP.

AG Opinion

The AG takes no position on whether Ribomustin or Levact should have been used as the reference medicinal product or when the applicable RDP period started running. Rather, he confines his opinion to the role of CMSs within the DCP and the ability of CMSs' national courts to review the decision of the national competent authority.

The AG begins by distinguishing the mutual recognition procedure (MRP), which, prior to 2004, was the only procedure by which national applications for MA could be made to multiple Member States from the DCP, which was added when Directive 2004/27 modified Directive 2001/83. The AG explains that the MRP may only be used by an applicant that has already been granted an MA in one Member State, that then acts as RMS. The CMSs are under a "clear and precise" obligation to recognise the scientific assessment of the RMS, which may only be called into question on public health grounds. Conversely, the AG views the DCP as a system of "co-decision logic" by which there must first be agreement on the product-related documents (namely, the assessment report, summary of product characteristics, labelling, and package leaflet) of the medicinal product. Only then, in the second step, can the CMSs adopt their own national MA.

Once agreement concerning the product-related documents has been reached, the AG states that CMSs cannot unilaterally revisit and reassess those documents. However, in the first step, a dialogue should take place between the CMSs and RMS. The AG recognises that the only potential objection of a CMS provided for by Directive 2001/83 is a 'potential serious risk to public health.' The AG notes that the question of whether RDP has expired does not initially appear to be an issue of public health. However, he reasons that, since the authorisation of a generic product relies on the data of the reference medicinal product, if those data are protected by RDP, and thus cannot be consulted, it is impossible to conduct any scientific assessment of the generic product. As such, the AG opines that agreement of the RMS and CMSs on the expiry of RDP is a preliminary, but indispensable, part of the approval process and each CMS is co-responsible for the conclusions reached.

Further, the AG states that, although the CMSs co-approve and become co-responsible for the resulting product-related documents, the MA that the CMSs grant is a formally independent administrative decision valid exclusively in their relevant national territory. As such, the AG "fail[s] to see any option other than to affirm the possibility of parallel and full judicial review of the respective marketing authorisation(s) issued in any of the Member States as a result of the [DCP]".

The AG acknowledges that his recommended solution may result in particularism as the court of each CMS will be able to adopt its own view on questions such as the RDP period, which may result in conflicting judgments. However, he suggests that this is the inevitable consequence of a decentralised system. If decentralised judicial review is an obstacle to a unified internal market for medicinal products, the AG suggests:

"... it would perhaps be ideal to voice those needs to the European legislature and initiate the adoption of an appropriate legislative regime reflecting those needs. I find it, however, unacceptable to first embrace a legislative framework which is quite decentralised, and then to use the argument of the need for a uniform regime to effectively deprive individual applicants of legal protection within that legislatively particularised regime. Simply put, market integration is not a good reason for creating black holes in judicial protection."

He adds that the obligation of sincere cooperation means that if the competent authorities of a CMS discover an issue possibly affecting the correctness of an MA granted by other CMSs, including the RMS, that competent authority should inform its counterparts accordingly. This may lead to reconsideration of existing national MAs through, for example, an ex officio review mechanism pursuant to the applicable national law.

Finally, the AG adds that if the legality of the original MA granted in another Member State is in issue, he believes that legality must be assessed in the Member State issuing the original authorisation, but he does not expand upon the relationship between this and judicial review in other Member States.


In 2008, the CJEU held in case C-452/06 (Synthon) that a CMS to which an application for MA under the MRP is made cannot call into question, on grounds other than those relating to the risk to public health, the assessment of the RMS, even where the decision of the RMS is in conflict with principles contained in the CMS's national legislation. Generic companies have relied on Synthon in certain Member States, which has become a potential hurdle for innovative pharmaceutical companies wishing to challenge the grant of generic MAs referring to their original MAs, either via the MRP or DCP. If the CJEU follows the AG's Opinion, each national competent authority that receives a generic MA application via the DCP may, as part of the process, take its own view on whether the RDP for the reference medicinal product has expired. Further, should the MA holder of the reference medicinal product disagree with the CMS's view on RDP, he may challenge the decision of the CMS in the national court.


1 See Opinion of Advocate General Bobek in Case C-557/16, Astellas Pharma GmbH.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions